KRN-7000

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
KRN-7000
Accession Number
DB12232
Description

KRN7000 has been used in trials studying the treatment of Lung Cancer, Chronic Hepatitis C, Hepatitis B, Chronic, Unspecified Adult Solid Tumor, Protocol Specific, and Prevention of GvHD in Patients With Hematological Malignancies Undergoing AHSCT.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 858.3224
Monoisotopic: 857.731983771
Chemical Formula
C50H99NO9
Synonyms
  • 1-O-(α-D-galactopyranosyl)-N-hexacosanoylphytosphingosine
External IDs
  • AGL-582
  • KRN 7000
  • KRN7000
  • RGI-2001

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with KRN-7000.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with KRN-7000.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with KRN-7000.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with KRN-7000.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as glycosphingolipids. These are sphingolipids containing a saccharide moiety glycosidically attached to the sphingoid base. Although saccharide moieties are mostly O-glycosidically linked to the ceramide moiety, other sphingolipids with glycosidic bonds of other types (e.g. S-,C-, or N-type) has been reported.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Sphingolipids
Sub Class
Glycosphingolipids
Direct Parent
Glycosphingolipids
Alternative Parents
Fatty acyl glycosides of mono- and disaccharides / Alkyl glycosides / Hexoses / O-glycosyl compounds / N-acyl amines / Oxanes / Secondary alcohols / Secondary carboxylic acid amides / Polyols / Acetals
show 7 more
Substituents
Acetal / Alcohol / Aliphatic heteromonocyclic compound / Alkyl glycoside / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Fatty acyl / Fatty acyl glycoside / Fatty acyl glycoside of mono- or disaccharide
show 21 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
glycophytoceramide (CHEBI:466659)

Chemical Identifiers

UNII
WX671898JF
CAS number
158021-47-7
InChI Key
VQFKFAKEUMHBLV-BYSUZVQFSA-N
InChI
InChI=1S/C50H99NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-45(54)51-42(41-59-50-49(58)48(57)47(56)44(40-52)60-50)46(55)43(53)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h42-44,46-50,52-53,55-58H,3-41H2,1-2H3,(H,51,54)/t42-,43+,44+,46-,47-,48-,49+,50-/m0/s1
IUPAC Name
N-[(2S,3S,4R)-3,4-dihydroxy-1-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octadecan-2-yl]hexacosanamide
SMILES

References

General References
Not Available
PubChem Compound
2826713
PubChem Substance
347828511
ChemSpider
2104816
ChEBI
466659
ChEMBL
CHEMBL384200
ZINC
ZINC000087496076
PDBe Ligand
AGH
PDB Entries
1zt4 / 2po6 / 3he6 / 3he7 / 3huj / 3to4 / 4en3 / 6bnk / 6v7y / 6v7z
show 1 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingPreventionAcute-graft-versus-host Disease / Graft Versus Host Disease (GVHD) / Graft Versus Host Disease, Acute / Prevention of aGVHD1
1CompletedTreatmentPlasma Cell Myeloma1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukemia (AML) / All / Blood Stem Cell Transplant Failure / Chemosensitive Hodgkin Lymphoma / Chronic Myelomonocytic Leukemia / CMML / Graft Versus Host Disease (GVHD) / Lymphoma, Hodgkins / MDS / MPN / Myelodysplastic Syndromes (MDS) / Myeloproliferative Disorders / Non-Hodgkin's Lymphoma (NHL)1
1WithdrawnTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD)1
1, 2CompletedTreatmentHepatitis B Chronic Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000358 mg/mLALOGPS
logP8.69ALOGPS
logP12.67ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)12.16ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area168.94 Å2ChemAxon
Rotatable Bond Count44ChemAxon
Refractivity244.6 m3·mol-1ChemAxon
Polarizability110.19 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 15:41 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates